# Clinical Trials Data EGFR - Document 50

# Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

## Clinical Trial: https://clinicaltrials.gov/study/NCT01391260

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologically confirmed diagnosis of non-squamous NSCLC; Stage \u2162A-\u2162B(not suitable for surgery) or stage \u2163(only single-site single transfer );\n\* Untreated patients, or who completed \u2264 2 cycles of first-line chemotherapy (chemotherapy regimen: paclitaxel, docetaxel + cisplatin) within the previous month;\n\* Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21 L858R substitution mutation);\n\* Patients must be informed of the investigational nature of the study and must sign an informed consent form;\n\* Presence of at least one measurable/evaluable according to RECIST criteria.\n\* ECOG performance Status 0-2 ;\n\* Patients must have a life expectancy \\> 12 weeks;\n\* Patients with laboratory values as follows:WBC\\>4.0 x 109/L; ANC\u22651.5 x 109/L; PLT\u2265100 x 109/L; HGB\u226510 g/dL; CR\u22641.5 x ULN; TBIL\\<1.5 x ULN; AST and ALT\u22641.5 x ULN; LDH\u22641.5 x ULN; AKP\u22645 x ULN;\n\* FEV 1\u22651.0L and \\>50% Corresponding normal values;\n\* Patient candidate to standard platinum-based chemotherapy;\n\* Patients must be nonpregnant and non-lactating.Patients of childbearing potential must implement an effective method of contraception during the study. All female Patients, except those who are postmenopausal or surgically sterilized, must have a negative pre-study serum or urine pregnancy test.\n\nExclusion Criteria:\n\n\* Any evidence of clinically active interstitial lung disease;\n\* Diagnosis of any other malignancy during the last 5 years, except for in situ carcinoma of cervix uterine and squamous cell carcinoma of the skin\uff1b\n\* Pregnancy or lactating\uff1b\n\* Serious concomitant infection;\n\* MI within preceding 6 months or symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmia;\n\* As judged by the investigator, any evidence of severe or uncontrolled systemic disease (eg, unstable or uncompensated respiratory, cardiac, hepatic, or renal disease);\n\* Patients who are not suitable to participate in the trial according to researchers.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Yes, a patient with an EGFR gene mutation (specifically exon 19 deletion mutation or exon 21 L858R substitution mutation) would be \*\*eligible\*\* for this trial, \*provided they also meet all the other inclusion criteria and do not meet any of the exclusion criteria.\* The inclusion criteria explicitly states: "Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21 L858R substitution mutation)."